In the phase III MONALEESA-3 trial, the efficacy of ribociclib plus fulvestrant was compared with that of fulvestrant on the patients with HR+, HER2− advanced breast cancer and included both first line and second-line patients. This evidence concerns the gene ERBB2 and breast cancer.